Read about our COVID-19 Response. Newsroom Newsroom Webinars and Podcasts Insights: Blog Latest News & Articles January 11, 2021 Cerus Corporation’s Chief Medical Officer Richard Benjamin and CEO William ‘Obi’ Greenman appear in The Untold Stories of Innovation podcast, where they discuss how and why Cerus was founded and describe the powerful ways that pathogen reduction could help lessen the negative impacts of a pandemic June 10, 2020 Cerus CEO William ‘Obi’ Greenman sat down with CNBC’s Mad Money host Jim Cramer for a discussion on Cerus, blood safety and our technology. April 1, 2020 BioWorld – Cerus looks to optimize convalescent plasma therapy November 3, 2018 Hematology Times – Breakthrough designation for pathogen-reduced cryoprecipitate Any links to third party Web pages from this Web site are provided for your convenience only. Cerus does not monitor, author, edit, or endorse any information provided in these third party pages and assumes no responsibility for the accuracy of their content. Global Headquarters 1220 Concord Avenue Concord, CA US 94520 +1 925.288.6000 European Headquarters Stationsstraat 79-D 3811 MH Amersfoort, Netherlands +31 (0) 33 49 60 600 Cookie Policy and Tracking Opt-out Guide Legal Privacy Policy Copyright (c) 2020 Cerus Corporation. INTERCEPT, INTERCEPT Blood System and Cerus are trademarks of Cerus Corporation. MKT-EN 00473 v.1.0 About Cerus About Cerus Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. Follow us on LinkedIn. By continuing to use this website, you agree to the use of cookies described in our Cookies Policy. OK